Evidence map›Paper›PMID 30883751›Full record

ArticleThe Journal of pathology2019

Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma.

Eric J Norris, Qing Zhang, Wendell D Jones, Darla DeStephanis, Ashley P Sutker, Chad A Livasy, Ram N Ganapathi, David L Tait, Mahrukh K Ganapathi

Open access · hybridAbstract read
In one paragraph

Article in The Journal of pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Neurotensin and Its Involvement in Female Hormone-Sensitive Cancers.International journal of molecular sciences · 2024
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Eric J NorrisLevine Cancer Institute, Atrium Health, Charlotte, NC, USA.ORCID 0000-0002-9204-5235
Qing ZhangLevine Cancer Institute, Atrium Health, Charlotte, NC, USA.
Wendell D JonesDepartment of Bioinformatics and Clinical Systems, Q2 Solutions - EA Genomics, Morrisville, NC, USA.ORCID 0000-0002-9676-5387
Darla DeStephanisLevine Cancer Institute, Atrium Health, Charlotte, NC, USA.
Ashley P SutkerLevine Cancer Institute, Atrium Health, Charlotte, NC, USA.
Chad A LivasyCarolinas Pathology Group, Charlotte, NC, USA.
Ram N GanapathiLevine Cancer Institute, Atrium Health, Charlotte, NC, USA.
David L TaitLevine Cancer Institute, Atrium Health, Charlotte, NC, USA.
Mahrukh K GanapathiLevine Cancer Institute, Atrium Health, Charlotte, NC, USA.
Levine Cancer Institute · USCarolinas Healthcare System · USQ2 Solutions (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High grade serous ovarian carcinoma (HGSC) without identifiable serous tubal intraepithelial carcinoma (STIC) within the fallopian tube (FT) occurs in approximately 50% of patients. The objective of this study was to use a multisite tumor sampling approach to study HGSC with and without STIC. RNAseq analysis of HGSC samples collected from multiple sites e.g. ovary, FT and peritoneum, revealed moderate levels of intrapatient heterogeneity in gene expression that could influence molecular profiles. Mixed-model ANOVA analysis of gene expression in tumor samples from patients with multiple tumor sites (n = 13) and patients with a single site tumor sample (n = 11) to compare HGSC-STIC to HGSC-NOSTIC identified neurotensin (NTS) as significantly higher (> two-fold change, False Discovery Rate (FDR) < 0.10) in HGSC-STIC. This data was validated using publicly available RNA-Seq datasets. Concordance between higher NTS gene expression and NTS peptide levels in HGSC-STIC samples was demonstrated by immunohistochemistry. To determine the role of NTS in HGSC, five ovarian cancer (OvCa) cell lines were screened for expression of NTS and its receptors, NTSR1 and NTSR3. Increased expression of NTS and NSTR1 was observed in several of the OvCa cells, whereas the NTSR3 receptor was lower in all OvCa cells, compared to immortalized FT epithelial cells. Treatment with NTSR1 inhibitor (SR48692) decreased cell proliferation, but increased cell migration in OvCa cells. The effects of SR48692 were receptor mediated, since transient RNAi knockdown of NTSR1 mimicked the migratory effects and knockdown of NTSR3 mimicked the anti-proliferative effects. Further, knockdown of NTSR1 or NTSR3 was associated with acquisition of distinct morphological phenotypes, epithelial or mesenchymal, respectively. Taken together, our results reveal a difference in a biologically active pathway between HGSC with and without STIC. Furthermore, we identify neurotensin signaling as an important pathway involved in cell proliferation and epithelial-mesenchymal transition in HGSC-STIC which warrants further study as a potential therapeutic target. © 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.

Indexed as

Carcinoma in SituCarcinoma, Ovarian EpithelialCystadenocarcinoma, SerousEpithelial CellsFallopian Tube NeoplasmsFallopian TubesFemaleHumansImmunohistochemistryNeurotensinOvarian NeoplasmsTumor Suppressor Protein p53NeurotensinTumor Suppressor Protein p53fallopian tubeneurotensinovarian cancerserous tubal intraepithelial carcinoma

Identifiers

PMID30883751
PMCPMC6619390
OpenAlexW2923132751

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.